
Post-Ablation Visual Auras a Sign of Transient Brain Injury?
New evidence suggests these auras may stem not from the puncture itself but from acute, procedure-related brain emboli affecting the visual cortex.
Gregory Marcus, MD, MAS
'These research findings have two distinct clinically relevant implications,' senior author Gregory Marcus, MD, MAS, cardiac electrophysiologist and endowed professor of atrial fibrillation research, University of California San Francisco (UCSF), told Medscape Medical News .
'First, they suggest that migraine symptoms with visual auras are less likely to be due to shunting of some neuroactive compound across interatrial septal defects and more likely occur as a result of occlusion of blood flow due to brain emboli,' Marcus said.
'Second, these findings demonstrate that, contrary to a long-held belief that these post-ablation MRI-detected small brain lesions are asymptomatic — in fact, they are often referred to as 'asymptomatic cerebral emboli' or 'ACEs' — these small acute brain lesions actually can, and perhaps often do, manifest in clinical symptoms,' he added.
'This finding could change the whole paradigm of treatment, perhaps focusing more on prevention of blood clots,' he added in a statement.
The study was published online on July 7 in the journal Heart Rhythm .
Brain Injury From Catheter Ablation?
The TRAVERSE trial enrolled 146 adults undergoing catheter ablation for ventricular arrhythmias; 74 were randomly allocated to ventricular access via transeptal puncture (creating a new, temporary hole between the left and right atria) and 72 to a retrograde approach (through the aortic valve, not requiring transseptal puncture).
All patients underwent high-resolution brain MRI the day after ablation and 63 (85%) in the transseptal group and 57 (79%) in the retrograde group completed a validated migraine questionnaire, a median of 38 days after the procedure.
There was no difference in post-ablation visual auras between the transseptal and retrograde aortic approaches (16% and 14%, respectively).
However, significantly more patients with acute brain emboli in the occipital or parietal lobes reported migraine-related visual auras (38% vs 11%; P < .01).
After multivariable adjustment, the presence of acute brain emboli in the occipital or parietal lobes was associated with a 12-fold greater likelihood of visual auras.
The data show that these post-ablation brain lesions are not 'clinically silent,' first author Adi Elias, MD, cardiac electrophysiology fellow at UCSF, noted in the statement. 'It may be the case that we haven't known what to look for and assessed for symptoms immediately without enough time for the subsequent visual auras that would occur,' Elias said.
Marcus elaborated on this point. He noted that prior studies have demonstrated that these small post-catheter ablation MRI-detected lesions can no longer be detected upon repeat imaging about a month later, demonstrating that the ability to detect these brain emboli is fleeting.
'Prior studies failed to demonstrate a relationship between migraine with visual aura and acute brain emboli, but perhaps they were too late to detect ephemeral MRI findings because the MRI had to be ordered and performed after symptoms develop,' Marcus said.
The TRAVERSE study is 'unique in that everyone had a brain MRI immediately after their catheter ablation procedure and likely in most, if not all cases, prior to the development of their visual aura symptoms,' he noted.
Importantly, said the researchers, the presence of brain emboli and visual auras was not associated with any significant change in cognition. Marcus said patients can be reassured that procedure-related brain emboli and visual auras typically fade within a month of the procedure.
An Under-Recognized Condition
Reached for comment, Mina Chung, MD, president of the Heart Rhythm Society, who wasn't involved in the study, told Medscape Medical News the occurrence of visual auras after ablation may be 'under-recognized.'
The fact that a prior history of visual auras was associated with visual auras at 1 month after the procedure, 'suggests some preexisting tendency toward such symptoms after these procedures,' said Chung, with the Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland.
'Reassuringly, there were no detectable differences in neurocognitive function,' said Chung.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


UPI
7 hours ago
- UPI
FDA closes investigation into deadly listeria outbreak
The Food and Drug Administration has closed an investigation into a listeria outbreak. It was responsible one death and at least 10 people being sickened. File Photo (2020) Jim Lo Scalzo/EPA July 24 (UPI) -- The Food and Drug Administration has closed an investigation into a listeria outbreak that killed one person and sickened 10 in several western states, health officials announced Thursday. People were sickened by the outbreak after consuming products produced by California-based Fresh & Ready Foods, officials announced Thursday. The recall applied to Ready-to-Eat products sold in Arizona, California, Nevada and Washington. Illnesses have been reported in California and Nevada. Dozens of items have been recalled, ranging from sandwiches and protein snacks to pasta dishes and croissants. "FDA is working with Fresh & Ready Foods on corrective and preventive actions," the FDA said in a statement. The recalled products were distributed between April 18th and April 28th in vending machines and breakrooms in corporate offices, medical buildings and healthcare facilities, the FDA said. The products had "Use By" dates between April 22nd and May19th. The FDA said it made the discovery during environmental testing at a production facility that turned up listeria on a piece of equipment. "Fresh & Ready Foods has taken immediate corrective actions including removing equipment to address this issue to ensure ongoing food safety and compliance with FDA guidelines," the statement continued.


Gizmodo
8 hours ago
- Gizmodo
Startup Claims Its Fusion Reactor Concept Can Turn Cheap Mercury Into Gold
Keep checking those gold prices—scientists have more news about the coveted metal. An energy startup claims it has the recipe for modern-day alchemy: turning mercury into gold inside a nuclear fusion reactor. Last week, Marathon Fusion, a San Francisco-based energy startup, submitted a preprint detailing an action plan for synthesizing gold particles via nuclear transmutation—essentially the process of turning one element into another by tweaking its nucleus. The paper, which has yet to undergo peer review, argues that the proposed system would offer a new revenue stream from all the new gold being produced, in addition to other economic and technological benefits. Specifically, the proposed method involves introducing mercury-198 into a fusion reactor and bombarding it with neutrons until it transforms into mercury-197, a much more unstable isotope of mercury. Because of its instability, mercury-197 decays into gold-197, the only stable isotope of gold. This process takes about 64 hours and relies on the steady release of high-energy neutrons popping out of the fusion of the hydrogen isotopes deuterium and tritium. A special 'blanket configuration' in the tokamak—a donut-shaped machine that uses magnetic fields to confine plasma—would separate gold production from the fusion plant's energy generation, according to the study authors. As a result, gold production wouldn't impinge on the plant's primary function to generate nuclear energy. This setup would allow the plant to 'simultaneously meet the fuel cycle requirements of [deuterium and tritium] fusion and achieve economically valuable production of gold,' the authors wrote in the paper. Assuming this is all feasible—and this remains a big theoretical assumption—reactors using this approach could produce around 11,000 pounds (5,000 kilograms) of gold every year per gigawatt of electricity generated, according to Marathon Fusion's chief executive, Kyle Schiller, and chief technology officer, Adam Rutkowski. To put this into perspective, around 3,000 metric tons of gold are mined each year. In an interview with the Financial Times, the two representatives stated that this 'byproduct' could double the revenue of the plant. But it's worth noting that the same process would likely result in the production of unstable and potentially radioactive isotopes of gold. As such, Rutkowski admitted, the gold would have to be stored for 14 to 18 years before it could be labeled radiation-safe. Experts who have (unofficially) reviewed the study claim the proposal presents thought-provoking points that warrant further discussion. 'On paper it looks great, and everyone so far that I talk to remains intrigued and excited,' Ahmed Diallo, a plasma physicist at the U.S. Department of Energy's national laboratory at Princeton who wasn't involved in the study, told the Financial Times. But all that shines is not gold—especially given the fact that, again, the paper has yet to be peer reviewed and does not offer any empirical demonstrations of the proposed setup. If this company is successful, however, perhaps we'll finally have achieved modern alchemy without giant particle accelerators. Although, in my opinion, effectively achieving alchemy through the use of giant accelerators is still pretty cool.
Yahoo
9 hours ago
- Yahoo
Sutter Health names new chief operating officer
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Name: Kevin Manemann Previous title: Executive vice president and chief integration officer, City of Hope New title: Chief operating officer, Sutter Health Manemann, an executive with more than two decades of leadership experience in large health systems, will be Sutter Health's next chief operating officer, the Sacramento, California-based system announced Tuesday. He'll be filling a role that's sat vacant since March, when previous COO Mark Sevco left Sutter to become the CEO of Pittsburgh-based Alleghany Health Network. Manemann, who assumes his new role on Sept. 15, was formerly an executive at Southern California-based City of Hope, a $6 billion cancer care system. Prior to that, Manemann held several leadership roles at Providence St. Joseph Health, the third-largest nonprofit health system in the U.S. — including leading a $10 billion division overseeing Northern and Southern California. Manemann was at Providence for more than 16 years, according to his LinkedIn. Manemann's selection as COO is the latest in a string of executive appointments for Sutter. The system named a new chief financial officer in May, a new chief scientific officer and chief nurse officer in January, and a new senior vice president of population health in December. At Sutter, Manemann will work closely with the system's chief physician executive to co-lead clinical and nonclinical operations, according to the release. Manemann's specific purview includes Sutter's operating structure, service lines, ambulatory surgery centers, nursing and home care. One of his priorities will be to support Sutter's ambulatory growth plans, the release said. The system, already a powerhouse in Northern California with more than two dozen hospitals, has been steadily snapping up more of the region's care delivery market, adding roughly 1,000 doctors and advanced practice clinicians in 2024. Sutter also opened or expanded a number of care centers last year, while announcing other capital projects, including an advanced neurological and neurosurgical care complex and a comprehensive cancer center. The system is also pursuing growth through a joint venture with SCAN Health Plan to offer new Medicare Advantage products next year, and a deal with GE Healthcare to integrate artificial intelligence into its operations. Amid these initiatives, Sutter's finances have remained relatively stable compared to some of its nonprofit peers, according to ratings agencies. Still, the system hasn't been immune to pressures hitting hospitals, including rising costs of labor and medical supplies. Sutter reported $142 million in operating income in 2024, down from $320 million the year prior. Though, hefty investment income in both years hiked Sutter's profits to $1 billion and $1.2 billion in 2024 and 2023, respectively. Sutter is also dealing with other operational challenges facing providers, including contract spats with major insurers. Sutter also been hit with multimillion-dollar settlements this year to settle legal actions over alleged anticompetitive behavior, retirement plan mismanagement and fraudulent billing for anesthesia services. Recommended Reading Sutter Health taps new CFO